American Heart Journal
Volume 151, Issue 3 , Pages 604-624 , March 2006

Pharmacological and surgical treatments for obesity

  • Tracy DeWald, PharmD, RD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Tracy DeWald, PharmD, RD, Duke Heart Center and Heart Failure Program, Duke University Medical Center, Box 3943 Durham, NC 27710.
    • ,
  • Lalita Khaodhiar, MD

      Affiliations

    • Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • Mark P. Donahue, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • George Blackburn, MD

      Affiliations

    • Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Received 8 March 2005 ,Accepted 8 March 2005.

References 

  1. Bray GA. Health hazards associated with overweight. In:  Bray GA editors. Contemporary diagnosis and management of obesity. Newtown (Pa): Handbooks in Health Care; 1998;p. 68–103
  2. United States Department of Health and Human Services , National Institutes of Health , National Heart, Lung, and Blood Institute . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda (Md): National Institutes of Health; 1998;[NIH Publication No. 98-4083]
  3. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;119:655–660
  4. Lean ME, Han TS, Seidell JC. Impairment of health and quality of life using new US federal guidelines for the identification of obesity. Arch Intern Med. 1999;159:837–843
  5. Sjostrom LV. Morbidity of severely obese patients. Am J Clin Nutr. 1992;55:508S–515S
  6. Halsted CH, Newton J, Phinney SD. Obesity and its health risks. Curr Opin Gastroenterol. 1996;12:204–209
  7. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res. 1998;6:97–106
  8. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–643
  9. Van Gaal LF. Dietary treatment of obesity. In:  Bray GA,  Bouchard C,  James WPT editor. Handbook of obesity. New York: Marcel Dekker; 1998;p. 875–890
  10. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs. 1992;43:713–733
  11. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute Funded Multimodal Intervention Study. Clin Pharmacol Ther. 1992;51:581–585
  12. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992;51:586–594
  13. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51:595–601
  14. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther. 1992;51:602–607
  15. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin Pharacol Ther. 1992;51:608–614
  16. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication. Clin Pharmacol Ther. 1992;51:615–618
  17. Weintraub M, Sundaresan PR, Cox C. Long-term weight control study. VI. Individual participant response patterns. Clin Pharmacol Ther. 1992;51:619–633
  18. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51:642–646
  19. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205–211
  20. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22:39–47
  21. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. Geneva (Switzerland): WHO; 1998;[WHO Technical Report Series, No. 894]
  22. Khan LK, Serdula MK, Bowman BA, et al. Use of prescription weight loss pills among U.S. adults in 1996-1998. Ann Intern Med. 2001;134:282–286
  23. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333:677–685
  24. Lee IM, Manson JE, Hennekens CH, et al. Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA. 1993;270:2823–2828
  25. Stevens J, Cai J, Pamuk ER, et al. The effect of age on the association between body-mass index and mortality. N Engl J Med. 1998;338:1–7
  26. Atkinson RL, Hubbard VS. Report on the NIH workshop on pharmacologic treatment of obesity. Am J Clin Nutr. 1994;60:153–156
  27. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276:1907–1915
  28. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology. 2001;120:669–681
  29. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev. 1999;20:805–875
  30. Cerulli J, Lomaestro BM, Malone M. Update on the pharmacotherapy of obesity. Ann Pharmacother. 1998;32:88–102
  31. Bray GA. A concise review on the therapeutics of obesity. Nutrition. 2000;16:953–960
  32. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Saf. 1999;20:119–131
  33. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343:1826–1832
  34. Physicians' desk reference. 54th ed.. Montvale (NJ): Medical Economics; 2000;
  35. Drug information handbook. 6th ed.. Hudson (Ohio): Lexi-Comp; 1998-1999;
  36. Orlistat for obesity. Med Lett Drugs Ther. 1999;41:55–56
  37. Inoue S. Clinical studies with mazindol. Obes Res. 1995;3:549S–552S
  38. King DJ, Devaney N. Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers. Br J Clin Pharmacol. 1988;26:607–611
  39. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335:609–616
  40. Lansberg L, Young JB. Physiology and pharmacology of the autonomic nervous system. In:  Braunwald E,  Fauci AS,  Kasper DL, et al. editor. Harrison's principles of internal medicine. 15th ed.. New York: McGraw-Hill; 2001;p. 438–445
  41. Tsujii S, Bray GA. Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists. Brain Res. 1992;587:226–232
  42. Bray GA. Evaluation of drugs for treating obesity. Obes Res. 1995;3:425S–434S
  43. Gundlah C, Martin KF, Heal DJ, et al. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther. 1997;283:581–591
  44. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998;56:1093–1124
  45. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999;33:968–978
  46. Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:575–584
  47. Van Gaal LF, Wauters MA, De Leeuw IH. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. Exp Clin Endocrinol Diabetes. 1998;106:35–40
  48. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res. 1995;3:553S–559S
  49. Connoley IP, Liu YL, Frost I, et al. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol. 1999;126:1487–1495
  50. Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 1999;23:1016–1024
  51. Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4:263–270
  52. Weintraub M, Rubio A, Golik A, et al. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther. 1991;50:330–337
  53. Jones SP, Smith IG, Kelly F. Long-term weight loss with sibutramine [abstract]. Int J Obes Relat Metab Disord. 1995;19:41
  54. Lean ME. Sibutramine—a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997;21:S30–S36
  55. Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very–low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179–184
  56. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet. 2000;356:2119–2125
  57. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–713
  58. Smith BK, York DA, Bray GA. Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate. Am J Physiol. 1999;277:R802–R811
  59. Dourish CT. Multiple serotonin receptors: opportunities for new treatments for obesity?. Obes Res. 1995;3:449S–462S
  60. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–588
  61. Jollis JG, Landolfo CK, Kisslo J, et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation. 2000;101:2071–2077
  62. Garattini S, Mennini T, Bendotti C, et al. Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system. Appetite. 1986;7:15–38
  63. Belohlavkova S, Simak J, Kokesova A, et al. Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels. J Appl Physiol. 2001;91:755–761
  64. Weissman NJ. Appetite suppressants and valvular heart disease. Am J Med Sci. 2001;321:285–291
  65. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2:1142–1145
  66. Carvajal A, Garcia del Pozo J, Martin de Diego I, et al. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis. Methods Find Exp Clin Pharmacol. 2000;22:285–290
  67. Bross R, Hoffer LJ. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am J Clin Nutr. 1995;61:1020–1025
  68. Wellbutrin. [package insert] Research Triangle Park (NC): Glaxo Wellcome; 2000;
  69. Croft H, Settle E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21:643–658
  70. Harto-Truax N, Stern WC, Miller LL, et al. Effects of bupropion on body weight. J Clin Psychiatry. 1983;44:183–186
  71. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994;14:170–179
  72. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9:544–551
  73. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther. 1999;21:454–463
  74. Scheen AJ, Lefebvre PJ. Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord. 1999;23:47–53
  75. Golay A, Bobbioni E. The role of dietary fat in obesity. Int J Obes Relat Metab Disord. 1997;21:S2–S11
  76. Bray GA, Popkin BM. Dietary fat intake does affect obesity!. Am J Clin Nutr. 1998;68:1157–1173
  77. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipostatin). Am J Clin Nutr. 1992;55:309S–313S
  78. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord. 1993;17:241–244
  79. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21:S12–S23
  80. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs. 1999;58:743–760
  81. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord. 1995;19:221–226
  82. James WP, Avenell A, Broom J, et al. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord. 1997;21:S24–S30
  83. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167–172
  84. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol. 1998;54:125–132
  85. Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years of treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8:49–61
  86. Lucas KH, Kaplan-Machlis B. Orlistat—a novel weight loss therapy. Ann Pharmacother. 2001;35:314–328
  87. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36:647–653
  88. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol. 1996;36:152–159
  89. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235–242
  90. Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol. 1994;46:405–410
  91. Pataky Z, Golay A. Effect of treatment with orlistat for one year on blood pressure in obese patients [abstract]. Int J Obes Relat Metab Disord. 1999;23:S175
  92. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21:1288–1294
  93. Prince DM, Welschenbach MA. Olestra: a new food additive. J Am Diet Assoc. 1998;98:565–569
  94. Thomson AB, Hunt RH, Zorich NL. Review article: olestra and its gastrointestinal safety. Aliment Pharmacol Ther. 1998;12:1185–1200
  95. Lawson KD, Middleton SJ, Hassall CD. Olestra, a nonabsorbed, noncaloric replacement for dietary fat: a review. Drug Metab Rev. 1997;29:651–703
  96. Patterson RE, Kristal AR, Peters JC, et al. Changes in diet, weight, and serum lipid levels associated with olestra consumption. Arch Intern Med. 2000;160:2600–2604
  97. Thornquist MD, Kristal AR, Patterson RE, et al. Olestra consumption does not predict serum concentrations of carotenoids or fat-soluble vitamins in free-living humans: early results from the sentinel site of the Olestra Post-Marketing Surveillance Study. J Nutr. 2000;130:1711–1718
  98. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care. 1999;22:1266–1272
  99. Everhart JE, Pettitt DJ, Bennett PH, et al. Duration of obesity increases the incidence of NIDDM. Diabetes. 1992;41:235–240
  100. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care. 1990;13:696–704
  101. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non–insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550–554
  102. Clark BF, Duncan LJ. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet. 1968;1:123–126
  103. Haupt E, Knick B, Koschinky T, et al. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab. 1991;17:224–231
  104. Hermann LS, Bitzen PO, Kjellstrom T, et al. Comparative efficacy of metformin and glibenclamide in patients with non–insulin-dependent diabetes mellitus. Diabetes Metab. 1991;17:201–208
  105. Munro JF, MacCuish AC, Marshall A, et al. Weight-reducing effect of diguanides in obese non-diabetic women. BMJ. 1969;2:13–15
  106. Papoz L, Job D, Eschwege E, et al. Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients. Diabetologia. 1978;15:373–380
  107. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non–insulin-dependent diabetes. Obes Res. 1998;6:47–53
  108. Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest. 1998;28:441–446
  109. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  110. Astrup A, Toubro S, Christensen NJ, et al. Pharmacology of thermogenic drugs. Am J Clin Nutr. 1992;55:246S–248S
  111. Jequier E, Munger R, Felber J. Thermogenic effects of various beta-adrenoceptor agonists in humans: their potential usefulness in the treatment of obesity. Am J Clin Nutr. 1992;55:249S–251S
  112. Tulp OL, Buck CL. Caffeine and ephedrine stimulated thermogenesis in LA-corpulent rats. Comp Biochem Physiol C. 1986;85:17–19
  113. Astrup A. Thermogenic drugs as a strategy for the treatment of obesity. Endocrine. 2000;13:207–212
  114. Liu YL, Toubro S, Astrup A, et al. Contribution of beta 3–adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord. 1995;19:678–685
  115. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methylxanthine mixtures: human studies. Int J Obes. 1986;10:467–481
  116. Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy-restricted diet. A double-blind trial. Int J Obes Relat Metab Disord. 1992;16:269–277
  117. Wiener I, Tilkian AG, Palazzolo M. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. Cathet Cardiovasc Diagn. 1990;20:51–53
  118. To LB, Sangster JF, Rampling D, et al. Ephedrine-induced cardiomyopathy. Med J Aust. 1980;2:35–36
  119. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833–1838
  120. Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang–guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord. 2001;25:316–324
  121. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements. Med J Aust. 1999;171:604–608
  122. Mertens IL, Van Gaal LF. Promising new approaches to the management of obesity. Drugs. 2000;60:1–9
  123. Collins P, Williams G. Drug treatment of obesity: from past failures to future successes?. Br J Clin Pharmacol. 2001;51:13–25
  124. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone–releasing acylated peptide from stomach. Nature. 1999;402:656–660
  125. Date Y, Kojima M, Hosada H, et al. Ghrelin, a novel growth hormone–releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141:4255–4261
  126. Schwartz MW, Woods SC, Porte D, et al. Central nervous system control of food intake. Nature. 2000;404:661–671
  127. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–1719
  128. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86:4753–4758
  129. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707–709
  130. Cummings DE, Weigle DS, Frayo RS, et al. Ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–1630
  131. Poykko SM, Kellokoski E, Horkko S, et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52:2546–2553
  132. Purnell JQ, Weigle DS, Breen P, et al. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab. 2003;88:5747–5752
  133. Tassone F, Broglio F, Destanfanis S, et al. Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. J Clin Endocrinol Metab. 2003;88:5478–5483
  134. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992–5995
  135. American College of Cardiology Scientific Sessions 2004, New Orleans, LA.
  136. Sjostrom LV. Mortality of severely obese subjects. Am J Clin Nutr. 1992;55:516S–523S
  137. Foley EF, Benotti PN, Borlase BC, et al. Impact of gastric restrictive surgery on hypertension in the morbidly obese. Am J Surg. 1992;163:294–297
  138. Carson JL, Ruddy ME, Duff AE, et al. The effect of gastric bypass surgery on hypertension in morbidly obese patients. Arch Intern Med. 1994;154:193–200
  139. Olsson SA, Petersson BG, Sorbris R, et al. Effects of weight reduction after gastroplasty on glucose and lipid metabolism. Am J Clin Nutr. 1984;40:1273–1280
  140. Herbst CA, Hughes TA, Gwynne JT, et al. Gastric bariatric operation in insulin-treated adults. Surgery. 1984;95:209–214
  141. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–350
  142. Sugerman HJ, Baron PL, Fairman RP, et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg. 1988;207:604–613
  143. Sugerman HJ, Fairman RP, Sood RK, et al. Long-term effects of gastric surgery for treating respiratory insufficiency of obesity. Am J Clin Nutr. 1992;55:597S–601S
  144. Kim CH, Sarr MG. Severe reflux esophagitis after vertical banded gastroplasty for treatment of morbid obesity. Mayo Clin Proc. 1992;67:33–35
  145. Sugerman HJ, Kellum JM, DeMaria EJ, et al. Conversion of failed or complicated vertical banded gastroplasty to gastric bypass in morbid obesity. Am J Surg. 1996;171:263–269
  146. Amaral JF, Tsiaris W, Morgan T, et al. Reversal of benign intracranial hypertension by surgically induced weight loss. Arch Surg. 1987;122:946–949
  147. Kellum JM, DeMaria EJ, Sugerman HJ. The surgical treatment of morbid obesity. Curr Probl Surg. 1998;35:791–858
  148. Sjostrom CD, Peltonen M, Wedel H, et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension. 2000;36:20–25
  149. National Institutes of Health Conference . Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115:956–961
  150. Payne JH, DeWind LT. Surgical treatment of obesity. Am J Surg. 1969;118:141–147
  151. Halverson JD, Wise L, Wazna MF, et al. Jejunoileal bypass for morbid obesity. A critical appraisal. Am J Med. 1978;64:461–475
  152. Kroyer JM, Talbert WM. Morphologic liver changes in intestinal bypass patients. Am J Surg. 1980;139:855–859
  153. Sugerman H. Gastric surgery for morbid obesity. In:  Zinner MJ editors. Maingot's abdominal operations. Stamford (Conn): Appleton & Lange; 1997;p. 1057–1077
  154. Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery. 1996;119:261–268
  155. Murr MM, Balsiger BM, Kennedy FP, et al. Malabsorptive procedures for severe obesity: comparison of pancreaticobiliary bypass and very very long limb Roux-en-Y gastric bypass. J Gastrointest Surg. 1999;3:607–612
  156. Lagace M, Marceau P, Marceau S, et al. Biliopancreatic diversion with a new type of gastrectomy: some previous conclusions revisited. Obes Surg. 1995;5:411–418
  157. Marceau S, Biron S, Lagace M, et al. Biliopancreatic diversion, with distal gastrectomy 250 cm and 50 cm limbs: long-term results. Obes Surg. 1995;5:302–307
  158. Marceau P, Hould FS, Simard S, et al. Biliopancreatic diversion with duodenal switch. World J Surg. 1998;22:947–954
  159. Gomez CA. Gastroplasty in morbid obesity. Surg Clin North Am. 1979;59:1113–1120
  160. Pace WG, Martin EW, Tetirick T, et al. Gastric partitioning for morbid obesity. Ann Surg. 1979;190:392–400
  161. Mason EE. Vertical banded gastroplasty for obesity. Arch Surg. 1982;117:701–706
  162. MacLean LD, Rhode BM, Sampalis J, et al. Results of the surgical treatment of obesity. Am J Surg. 1993;165:155–160
  163. Nightengale ML, Sarr MG, Kelly KA, et al. Prospective evaluation of vertical banded gastroplasty as the primary operation for morbid obesity. Mayo Clin Proc. 1991;66:773–782
  164. Howard L, Malone M, Michalek A, et al. Gastric bypass and vertical banded gastroplasty—a prospective randomized comparison and 5-year follow-up. Obes Surg. 1995;5:55–60
  165. Sugerman HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg. 1987;205:613–624
  166. Jones KB. Experience with the Roux-en-Y gastric bypass, and commentary on current trends. Obes Surg. 2000;10:183–185
  167. Bo O, Modalsli O. Gastric banding, a surgical method of treating morbid obesity: preliminary report. Int J Obes. 1983;7:493–499
  168. Kuzmak L. Stoma adjustable silicone gastric banding. Probl Gen Surg. 1992;9:298–317
  169. Belachew M, Legrand M, Vincent V, et al. Laparoscopic placement of adjustable silicone gastric band in the treatment of morbid obesity: how to do it. Obes Surg. 1995;5:66–70
  170. O'Brien PE, Brown WA, Smith A, et al. Prospective study of a laparoscopically placed, adjustable gastric band in the treatment of morbid obesity. Br J Surg. 1999;86:113–118
  171. Belachew M, Legrand M, Vincent V, et al. Laparoscopic adjustable gastric banding. World J Surg. 1998;22:955–963
  172. Doldi SB, Micheletto G, Lattuada E, et al. Adjustable gastric banding: 5-year experience. Obes Surg. 2000;10:171–173
  173. Forsell P, Hellers G. The Swedish Adjustable Gastric Banding (SAGB) for morbid obesity: 9-year experience and a 4-year follow-up of patients operated with a new adjustable band. Obes Surg. 1997;7:345–351
  174. Westling A, Bjurling K, Ohrvall M, et al. Silicone-adjustable gastric banding: disappointing results. Obes Surg. 1998;8:467–474
  175. Mason EE, Ito C. Gastric bypass. Ann Surg. 1969;170:329–339
  176. Ito C, Mason EE, Besten LD. Experimental studies on gastric bypass versus standard ulcer operations. Tohoku J Exp Med. 1969;97:269–277
  177. Griffen WO, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg. 1977;186:500–509
  178. Alden JF. Gastric and jejunoileal bypass. A comparison in the treatment of morbid obesity. Arch Surg. 1977;112:799–806
  179. Brolin RE, Kenler HA, Gorman JH, et al. Long-limb gastric bypass in the superobese. A prospective randomized study. Ann Surg. 1992;215:387–395
  180. Meryn S, Stein D, Straus EW. Pancreatic polypeptide, pancreatic glucagons and enteroglucagon in morbid obesity and following gastric bypass operation. Int J Obes. 1986;10:37–42
  181. Kellum JM, Kuemmerle JF, O'Dorisio TM, et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg. 1990;211:763–770
  182. Sugerman HJ, Londrey GL, Kellum JM, et al. Weight loss with vertical banded gastroplasty and Roux-Y gastric bypass for morbid obesity with selective versus random assignment. Am J Surg. 1989;157:93–102
  183. Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic gastric bypass, Roux-en-Y: preliminary report of five cases. Obes Surg. 1994;4:353–357
  184. Naitoh T, Gagner M, Garcia-Ruiz A, et al. Hand-assisted laparoscopic digestive surgery provides safety and tactile sensation for malignancy or obesity. Surg Endosc. 1999;13:157–160
  185. Schauer PR, Ikramuddin S, Gourash WF. Laparoscopic Roux-en-Y gastric bypass: a case report at one-year follow-up. J Laparoendosc Adv Surg Tech A. 1999;9:101–106
  186. de la Torre RA, Scott JS. Laparoscopic Roux-en-Y gastric bypass: a totally intra-abdominal approach—technique and preliminary report. Obes Surg. 1999;9:492–498
  187. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y—500 patients: technique and results, with 3-60 month follow-up. Obes Surg. 2000;10:233–239

PII: S0002-8703(05)00253-X

doi: 10.1016/j.ahj.2005.03.007

American Heart Journal
Volume 151, Issue 3 , Pages 604-624 , March 2006

Article Tools